R G Humphries
Overview
Explore the profile of R G Humphries including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin J, Tomlinson W, Kirk I, Kim Y, Humphries R, Kunapuli S
Br J Pharmacol
. 2001 Jun;
133(4):521-8.
PMID: 11399669
P2Y receptor activation in many cell types leads to phospholipase C activation and accumulation of inositol phosphates, while in blood platelets, C6-2B glioma cells, and in B10 microvascular endothelial cells...
2.
Jarvis G, Humphries R, Robertson M, Leff P
Br J Pharmacol
. 2000 Feb;
129(2):275-82.
PMID: 10694233
1. In the present study we have investigated the roles of P2Y(1) and P(2T) receptor subtypes in adenosine 5'-diphosphate (ADP)-induced aggregation of human platelets in heparinized platelet rich plasma. 2....
3.
Ingall A, DIXON J, Bailey A, Coombs M, Cox D, McInally J, et al.
J Med Chem
. 1999 Feb;
42(2):213-20.
PMID: 9925726
The platelet P2T receptor plays a major role in platelet aggregation, and its antagonists are predicted to have significant therapeutic potential as antithrombotic agents. We have explored analogues of adenosine...
4.
Fagura M, Dainty I, McKay G, Kirk I, Humphries R, Robertson M, et al.
Br J Pharmacol
. 1998 Jun;
124(1):157-64.
PMID: 9630355
1. In the present study we have classified the receptor(s) mediating increases in intracellular calcium concentration ([Ca2+]i) in human washed platelets and compared the pharmacological profile obtained with that observed...
5.
Tomkinson N, Marriott D, Cage P, Cox D, Davis A, Flower D, et al.
J Pharm Pharmacol
. 1996 Feb;
48(2):206-9.
PMID: 8935173
FPL67085MX represents the first in a class of novel, highly potent and selective P2T purinoceptor antagonists which are inhibitors of adenosine diphosphate (ADP)-induced platelet aggregation in-vitro. In an early series...
6.
Humphries R, Tomlinson W, CLEGG J, Ingall A, Kindon N, Leff P
Br J Pharmacol
. 1995 Jul;
115(6):1110-6.
PMID: 7582510
1. The role of endogenous ADP in platelet aggregation in vivo remains unclear due to the lack of suitable P2T-antagonist probes. This paper describes the potency, selectivity and specificity of...
7.
A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis
Humphries R, Robertson M, Leff P
Trends Pharmacol Sci
. 1995 Jun;
16(6):179-81.
PMID: 7652925
No abstract available.
8.
MILLAR J, Wilson W, Carr R, Humphries R
J Ocul Pharmacol Ther
. 1995 Jan;
11(1):11-23.
PMID: 8535953
A novel technique is described in which the effect of the beta-adrenoceptor antagonists timolol and carteolol, and the vasodilators sodium nitroprusside (SNP) and verapamil on intraocular pressure (IOP) and the...
9.
Humphries R, Tomlinson W, Ingall A, Cage P, Leff P
Br J Pharmacol
. 1994 Nov;
113(3):1057-63.
PMID: 7858849
1. ADP-dependent platelet aggregation is mediated by the P2T-purinoceptor and is specifically inhibited by ATP, which is a competitive P2T-purinoceptor antagonist. However, ATP functions as an agonist at other P2-purinoceptor...
10.
Humphries R, Carr R, Nicol A, Tomlinson W, OConnor S
Br J Pharmacol
. 1991 Mar;
102(3):565-6.
PMID: 1364819
Intravenous infusion of L-NG-nitro-arginine, an inhibitor of endothelial nitric oxide (NO) synthesis, produced vasoconstriction in the coronary, cerebral, renal and duodenal vascular beds of the conscious rabbit. In this study,...